William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
News|Articles|June 26, 2026
OTC Naloxone Expands Access, but Cost and Distribution Gaps Still Limit Overdose Prevention
Fact checked by: Ron Panarotti
In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology & Research at the Addictions, Drug & Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.
Advertisement
Advertisement
Expanding OTC access to naloxone nasal spray represents an important step toward making the opioid overdose reversal medication more widely available. However, cost, geographic availability, public awareness, and persistent misconceptions may continue to prevent naloxone from reaching individuals who are most likely to experience or witness an overdose.
Related to this article
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
Advertisement
Advertisement